Bacterial expression systems are gaining traction as a versatile solution for protein production, prompting a strategic partnership between Swedish contractor NorthX Biologics and Austrian technology firm enGenes Biotech. The collaboration aims to develop an integrated, E.coli-based protein production platform that addresses the evolving needs of the biopharmaceutical sector.
While E.coli-based systems have been utilized since the 1970s for producing recombinant proteins like insulin and growth hormone, recent advancements in strain engineering are broadening their applicability. These systems are typically favored for their cost-effectiveness and speed, but the increasing complexity of biologics is driving biopharmaceutical firms to reconsider their potential for commercial-scale production.
Ola Tuvesson, CTO at NorthX, highlights that the growth of biosimilars, peptide therapeutics, and antibody fragments is fueling this demand. The partnership seeks to streamline the development pathway from strain design to GMP manufacturing, reducing fragmentation and enhancing efficiency. By integrating these processes, NorthX and enGenes aim to provide biopharma clients with a robust and scalable manufacturing service, ultimately supporting faster development timelines and more effective production strategies.
Use the database as your supply chain compass →
